CURRENT ISSUE

Genetic Engineering " Biotechnology News - Current Issue

(view larger image)

SUBSCRIBE

AD LINK

Visit GEN on Twitter!

GEN News Highlights

  • Print
  • Share
  • More GEN News Highlights

Nov 17 2009, 10:26 AM EST

PPD and Janssen Ally on Therapies for Irritable Bowel Syndrome and Bacterial Infections

GEN News Highlights

PPD has in-licensed two compounds from Janssen Pharmaceutica, both of which are ready to begin Phase II trials. One candidate is designed to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other for complicated skin and skin structure and respiratory infections.

PPD will be responsible for Phase II development, and once completed Janssen has the option to resume development of each compound. In exchange, PPD will receive up to $330 million in clinical and sales milestones plus royalties. If Janssen does not buy back a program, PPD will have the option to continue developing the compound and will pay $250 million in clinical and sales milestones plus royalties.

“Our agreements with Janssen diversify and strengthen our compound partnering portfolio and may gain us entry into two large markets,” said Fred Eshelman, executive chairman of PPD. “The IBS-d market holds significant drug development potential because of the lack of approved products for this indication, and new antibiotics are needed to address increasing incidences of resistant strain bacterial infections.”

The IBS-d compound is a potential first-in-class locally active mu opioid receptor agonist and delta opioid receptor antagonist. The antibacterial molecule is a broad-spectrum fluoroquinolone with activity against Gram positive and Gram negative bacteria and MRSA. It is being developed as both an oral and intravenous therapy to treat skin and respiratory infections.

 

♦♦♦
Related News

PPD to Spin Out Compound-Partnering Segment, Acquire Chinese CRO, and Invest $100M in Celtic Therapeutics (Oct. 28, 2009)
Janssen to Invest at least $38M in CNS Collaboration with NeuroSearch (Aug. 17, 2009)
Galapagos Earns $4.7M in RA Alliance with Janssen (May 28, 2009)
PPD Sells Research Center for $46M and Picks Up Magen for $14.5M (Apr. 3, 2009)
PPD to Acquire AbCRO (Feb. 9, 2009)

  • Print
  • Share
  • More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:

HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.


CAREER CENTER

Visit the GEN Career Center

for the latest biotech employment opportunities.
Start your search HERE!

visit the Career Center

WEBINARS


view all webinars

GEN and Scintellix bring you the Cryptogram Challenge: RNAi!

PODCASTS

INTERVIEW: NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates ...MORE

MOST POPULAR

News

Articles

Blogs